Discussing a powerful economic tool that can help your CNS molecule survive portfolio review will be Dr. Bruce Leuchter, Assistant Professor of Psychiatry & Director, Clinical Neuropsychiatry and Neurostimulation Therapies at Weill Cornell Medical College and former Emerging Biotechnology Analyst at Goldman Sachs & Company. Bruce will be joined by MedAvante’s Chief Medical Officer, Dr. Mike Detke.

Hosted by MedAvante CEO Paul Gilbert, this webinar event will provide convincing evidence that selecting an effective strategy to reduce this risk represents the most important economic decision any clinical development leader will make, and a powerful way to impact the financial value of new drug candidates.